Citrate Buffer Stabilization of Anti-Rabies Antibody Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for monoclonal antibodies, particularly for rabies virus, face challenges in maintaining stability due to chemical and physical instabilities, making it difficult to predict suitable excipients and optimal conditions for long-term storage, especially under varying temperatures and humidity conditions.
Innovation Solution
Aqueous solutions comprising citrate buffer, a tonicity agent, and a surfactant, specifically polysorbate 80, are used to stabilize the anti-rabies antibodies CR57 and CR4098, or their functional variants, maintaining stability for at least 12 months at 2-8°C and retaining biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If phosphate buffer is used to prepare anti-rabies antibodies, then the formulation is simple and easy to prepare, but the antibody stability deteriorates and biological activity is lost over time
Solution Approach 1:
The patent changes the buffer system parameter from phosphate buffer to citrate buffer, and adjusts the pH range to 5.5-6.5. This parameter change resolves the contradiction by providing a buffer system that maintains both formulation simplicity and antibody stability, preventing degradation and aggregation observed with phosphate buffer
Solution Approach 2:
The patent creates a composite formulation system combining citrate buffer with specific excipients (surfactants like polysorbate 80, amino acids, sugars) in defined concentrations. This composite approach resolves the contradiction by synergistically combining multiple components that collectively maintain antibody stability while keeping the formulation straightforward to prepare
2Stability of the object's composition
If surfactant is added to phosphate buffer formulation, then the formulation aims to prevent aggregation, but antibody instability increases and biological activity is reduced
Solution Approach 1:
The patent changes the buffer parameter from phosphate to citrate, which fundamentally alters how surfactants interact with the antibody. In citrate buffer at pH 5.5-6.5, surfactants like polysorbate 80 effectively prevent aggregation without causing the instability and biological activity loss observed in phosphate buffer systems
Solution Approach 2:
The citrate buffer acts as an intermediary medium that mediates between the surfactant and antibody. It creates an environment where surfactants can perform their aggregation-preventing function without triggering the harmful effects seen in phosphate buffer, thus resolving the contradiction through a mediating buffer system
3Reliability
If multiple excipients are added to achieve optimal stability, then the formulation becomes complex, but finding suitable conditions for two different monoclonal antibodies becomes even more difficult
Solution Approach 1:
The patent identifies a universal formulation system (citrate buffer pH 5.5-6.5 with specific excipient classes) that works for both CR57 and CR4098 antibodies simultaneously. This multi-functional approach resolves the contradiction by providing a single formulation platform that achieves optimal stability for multiple different monoclonal antibodies without requiring separate complex optimization for each
Solution Approach 2:
The patent establishes specific parameter ranges (citrate buffer concentration, pH 5.5-6.5, surfactant concentration ranges, amino acid concentrations) that create a stable environment for multiple antibodies. These defined parameters simplify the formulation process while maintaining stability, resolving the contradiction between complexity and reliability
4Ease of operation
If antibodies are stored at elevated temperatures and humidity, then transport and distribution become easier, but physical and chemical instability increases leading to degradation
Solution Approach 1:
The patent incorporates stabilizing excipients (surfactants, amino acids, sugars) in the formulation before storage. These excipients act as a cushioning protective layer that prevents degradation during exposure to elevated temperatures and humidity during transport, resolving the contradiction between transport ease and stability maintenance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations ensure the stability and biological activity of the antibodies, with minimal degradation and aggregation, even under elevated temperatures and humidity, making them suitable for prolonged storage and administration.
Implementation Method 1
comprise citrate buffer
Implementation Method 2
a surfactant, specifically polysorbate 80
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides pharmaceutical antibody formulations, in particular liquid pharmaceutical formulations comprising anti-rabies virus antibodies. The formulations can be used in the post exposure prophylaxis of rabies.